SIGMA-SYSTEMS
2.5.2017 11:02:08 CEST | Business Wire | Press release
Sigma Systems, a global leader in catalog-driven software, has appointed Catherine Michel as Chief Technology Officer (CTO).
Michel previously served as Chief Strategy Officer (CSO) on Sigma’s leadership team, and currently sits on the TM Forum Executive Committee, has been named as one of the most powerful people in the telecoms industry by Global Telecoms Business, and is a public advocate and mentor for women in telco and IT. As Sigma’s Chief Technology Officer, Catherine is responsible for the company's product portfolio and strategy.
“Catherine is a globally respected member of the IT and communications technology community, and we are very fortunate to have her on the Sigma team. She has an excellent track record of innovation within the software development arena and is a highly strategic thinker. Catherine has been vital in driving Sigma’s product portfolio forward, and will continue to do so in her new role in the coming months and years. Catherine is a key spokesperson for the company at events and technology forums across the globe,” said Tim Spencer, Sigma’s President and CEO.
Prior to her roles at Sigma, Michel was the founder and CTO of Tribold, where she was the principal architect of the company's products and solutions portfolio. Tribold was acquired by Sigma in 2013. Prior to co-founding Tribold, she was a senior executive in Accenture's Communications and High Tech practice, devising and delivering business strategy and large-scale B/OSS solutions globally.
“Sigma is on the cutting edge of delivering technology solutions that enable operators to truly transform into agile digital service providers,” observed Michel. “I continue to be excited about the position we’ve achieved in the market and the opportunities ahead of us.”
Catherine will be speaking at TM Forum Live! in Nice with Sigma customer Windstream. The joint presentation will outline how Windstream developed, governed and executed a widespread digital transformation program in parallel with a major acquisition and SDN deployment. As a key strategic partner, Sigma is supporting Windstream’s transition to an agile delivery organization with the adoption of catalog-driven Agile B/OSS. Sigma’s portfolio is designed to support CSPs like Windstream to embrace digital innovation and enable the rapid launch and fulfilment of new products and services without entirely dismantling existing legacy systems.
Presentation Details:
May 15th
, 11:15am
TM Forum
Live!
Palais des Congrès Acropolis, Nice, France
About Sigma Systems (
sigma-systems.com
or Twitter @SigmaSystems)
Sigma Systems is a global leader in
catalog-driven software solutions for communications, media, and
high-tech companies. It serves over 80 customers in 40 countries with
its award-winning products.
The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management and Provisioning products, which can be deployed in the cloud or on-premise. Sigma utilizes an agile approach to implementing its B/OSS products for its customers.
Sigma has offices in North and South America, Europe and Asia, with technology and integration partners in over 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005185/en/
Contact:
Sigma Systems
Noor Manji, 416-943-9696
Manager, Corporate
Communications
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom